[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349718-105":59,"doc-detail-349718-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancing-adoptive-t-cell-therapy-in-ovarian-cancer-barriers-innovations-and-emerging-platforms","Advancing adoptive T cell therapy in ovarian cancer - barriers, innovations, and emerging platforms","","Adoptive cell therapy (ACT) shows curative potential in select cancers, yet translating it to ovarian cancer is limited by tumor heterogeneity, immune exclusion, and an immunosuppressive tumor microenvironment. This review synthesizes current ACT modalities, including TILs, TCR-engineered cells, and CAR-T approaches, and evaluates emerging strategies such as BiTE-secreting cells, dual-targeting platforms, and synthetic antigen receptors. It discusses barriers like T-cell persistence limits, antigen escape, and exhaustion, and outlines solutions including cytokine armoring, checkpoint and metabolic modulation, and gene editing, plus safety-focused synthetic circuits. It also emphasizes allogeneic and in vivo engineering and the role of spatial transcriptomics, single-cell profiling, and machine learning for biomarker-driven patient selection, aiming to accelerate potent, durable, personalized ACT.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancing-adoptive-t-cell-therapy-in-ovarian-cancer-barriers-innovations-and-emerging-platforms/349718/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancing-adoptive-t-cell-therapy-in-ovarian-cancer-barriers-innovations-and-emerging-platforms/349718.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is adoptive cell therapy harder to translate to ovarian cancer than to other cancers?","Question",{"text":112,"@type":113},"Multiple factors hinder translation, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major barriers to ACT efficacy in ovarian cancer does the review cover?",{"text":117,"@type":113},"Key barriers include limited T-cell persistence, antigen escape, and T-cell exhaustion within the tumor environment.",{"name":119,"@type":110,"acceptedAnswer":120},"What strategies are discussed to improve ACT performance and safety?",{"text":121,"@type":113},"The review highlights cytokine armoring, checkpoint modulation, metabolic reprogramming, gene editing, and safety engineering using logic-gated or self-regulating synthetic circuits.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349718,1790333608,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Open access Review  \n Advancing adoptive T cell therapy in  \novarian cancer: barriers, innovations, and emerging platforms  \nGabriel Nascimento De Souza Santos,1 Celia DeJohn  ,2 Suzanne M Hess,2 Emese Zsiros  ,2 A J Robert McGray  1  \nTo cite: Santos GNDS, DeJohn C, Hess SM, et al. Advancing adoptive T cell therapy in ovarian cancer:  \nbarriers, innovations, and emerging platforms. Journal for ImmunoTherapy of Cancer 2026;14:e013285 . doi:10 . 1136/ jitc-2025-013285  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013285](jitc-2025-013285)) .  \nGNDSS and CD contributed equally.  \nAccepted 17 December 2025  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA 2Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA  \nCorrespondence to  \nA J Robert McGray;  \najrobert. mcgray@roswellpark. org  \nABSTRACT  \nAdoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment. This review provides a comprehensive analysis of current ACT modalities, including tumorinfiltrating lymphocytes, T cell receptor-engineered, and chimeric antigen receptor-T cell therapies, as well as emerging approaches such as bispecific T cell engager (BiTE)-secreting T cells, dual-targeting platforms, and synthetic antigen receptors. We examine their application in OC and contextualize relevant findings using insights from other solid tumors. Key barriers, including limited T cell persistence, antigen escape, and T cell exhaustion, are explored alongside strategies to enhance efficacy through cytokine armoring, checkpoint modulation, metabolic reprogramming, and gene editing. We further highlight innovations in safety engineering, including logic-gated and self-regulating synthetic circuits, to mitigate toxicity and improve precision. Additional attention is given to the evolving role of allogeneic products and in vivo engineering as scalable solutions. Finally, we emphasize the critical value of integrating high-dimensional tools such as spatial transcriptomics, single-cell profiling, and machine learning to refine ACT design, identify biomarkers of response, and support patient selection and stratification. Collectively, these advances offer a roadmap for overcoming the unique immunologic barriers to ACT in OC and accelerating the development of more potent, durable, and personalized T cell-based strategies.  \nINTRODUCTION  \nOvarian cancer (OC) is the fifth leading cause of cancer-related death among women and remains the most lethal gynecologic malignancy worldwide. Standard front-line treatment consists of cytoreductive surgery followed by platinum-based chemotherapy combined with a taxane, typically carboplatin and paclitaxel.1 In patients with advanced-stage disease for whom primary cytoreduction is not feasible, neoadjuvant chemotherapy followed by interval debulking is a commonly used alternative to upfront  \nsurgery.2 3 Despite high initial response rates,>70% of patients experience disease recurrence within 3 years.4 5 While some patients with platinum-sensitive relapses benefit from additional chemotherapy, treatment options for platinum-resistant disease are limited and typically offer low response rates and shortlived benefit.6  \nFor select patients, targeted therapies such as bevacizumab,7 poly (ADP-ribose) polymerase inhibitors (PARPi),8 or combinations of PARPi with anti-angiogenic agents9 10 can prolong progression-free survival. More recently, antibody drug conjugates (","cbCaipKQTkIYiyCU","https://ap.wps.com/l/cbCaipKQTkIYiyCU","pdf",2255894,17,"English","# Abstract\n# Introduction\n# ACT Modalities: TILs, T cell receptors, and CAR-T","[{\"question\":\"Why is adoptive cell therapy harder to translate to ovarian cancer than to other cancers?\",\"answer\":\"Multiple factors hinder translation, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment.\"},{\"question\":\"What major barriers to ACT efficacy in ovarian cancer does the review cover?\",\"answer\":\"Key barriers include limited T-cell persistence, antigen escape, and T-cell exhaustion within the tumor environment.\"},{\"question\":\"What strategies are discussed to improve ACT performance and safety?\",\"answer\":\"The review highlights cytokine armoring, checkpoint modulation, metabolic reprogramming, gene editing, and safety engineering using logic-gated or self-regulating synthetic circuits.\"}]","Advancing adoptive T cell therapy in ovarian cancer - barriers, innovations, and emerging platforms | PDF",1790085195,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c47e0d7d977919841f0f555520d16ef5.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1269d9bbefeba551f3dc5dd48ce67692.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0a0bfa2b91496d659a45c0339dcb55a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd79d46e515984a033a8d1329363f4a4.webp",980,1306]